MOLOGEN AG / Miscellaneous 18.05.2009 Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Berlin, May 18, 2009 - Patients' responses to the newly designed anti-cancer drug MGN1703 of MOLOGEN AG exceeded expectations in clinical trial. Therefore the biopharmaceutical company decided to extent the on-going phase 1 study for a further dose increase. The preliminary safety results show a favorable safety profile of MGN1703 in all patients treated with different doses of the cancer drug for up to 6 weeks. The evaluation of systemic and local tolerability of the treatment exhibited very good results up to the dose of 30 mg. A stable disease after completion of 6 weeks treatment was observed in over 40 per cent of the patients. Until now, four of the responding patients were treated for further 6 weeks with the cancer drug. After completion of the extension therapy, an ongoing stable disease was still observed in two of these patients. The efficacy concept has been further confirmed by investigations of the relationship between the administered dose and the drug distribution in the body (pharmacokinetics) conducted within the scope of this clinical trial. Based on the favorable safety and pharmacokinetic results in all treatment groups, Mologen AG has decided to extent the on-going study for a further dose increase. Additional quantities of the cancer drug are currently being manufactured. MOLOGEN expects to announce first results from this additional dose group in the fourth quarter 2009. The company is currently intensively engaged in preparing additional clinical trials investigating the efficacy of MGN1703. A clinical trial phase 2 with colorectal cancer patients is scheduled to start this year. Contact: Jörg Petrass Email: investor@mologen.com Telephone: +49-30-84 17 88-13 Fax: +49-30-84 17 88-50 Kirchhoff Consult AG Dr Kay Baden Email: baden@kirchhoff.de Telephone: +49-40-60 91 86 39 DGAP 18.05.2009 --------------------------------------------------------------------------- Language: English Issuer: MOLOGEN AG Fabeckstraße 30 14195 Berlin Deutschland Phone: 030 / 841788-0 Fax: 030 / 841788-50 E-mail: info@mologen.com Internet: www.mologen.com ISIN: DE0006637200 WKN: 663720 Listed: Regulierter Markt in Frankfurt; Freiverkehr in Berlin, München, Hamburg, Düsseldorf, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Mologen AG: Positive preliminary results on clinical trial with anti-cancer drug
| Source: EQS Group AG